Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Community Hospital

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Community Hospital. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2017-001406-15 Sponsor Protocol Number: NACATB Start Date*: 2018-07-19
    Sponsor Name:Fundació Clínic per la Recerca Biomèdica
    Full Title: Adequate duration of antibiotic treatment in community acquired pneumonia categorized by pneumonia severity index (PSI)
    Medical condition: Community Acquired Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002390-28 Sponsor Protocol Number: INSPIRE Start Date*: 2022-10-10
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: IMMUNOTHERAPY NAVIGATED BY SERUM PRESEPSIN FOR INFECTIONS OF THE RESPIRATORY TRACT: THE INSPIRE DOUBLE-BLIND, RANDOMIZED, PHASE IIa EXPLORATORY TRIAL
    Medical condition: community-acquired pneumonia, hospital-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    20.0 100000004862 10076918 Hospital acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006842-33 Sponsor Protocol Number: MOX-06191 Start Date*: 2007-11-23
    Sponsor Name:Fundación para Investigación y Desarrollo en el Área Cardiovascular del Hospital Clínico San Carlos
    Full Title: Estudio Piloto Comparativo de Eficacia, Tolerancia y Seguridad de Moxifloxacino VO frente a Levofloxacino en Terapia Secuencial en Adultos Inmunocompetentes con Neumonía Adquirida en la Comunidad.
    Medical condition: Neumonía adquirida en la comunidad
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004566-14 Sponsor Protocol Number: SanteonCAP Start Date*: 2012-01-09
    Sponsor Name:
    Full Title: Santeon-CAP study Dexamethasone in community-acquired pneumonia.
    Medical condition: Patients with a community-acquired pneumonia who are admitted to the hospital.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005096-93 Sponsor Protocol Number: 070864 Start Date*: 2009-09-03
    Sponsor Name:Jordi Carratalá
    Full Title: SIMVASTATINA EN LA NEUMONIA ADQUIRIDA EN LA COMUNIDAD QUE REQUIERE HOSPITALIZACION. ESTUDIO ALEATORIZADO, DOBLE-CIEGO, CONTROLADO CON PLACEBO (SIMVASTATIN IN COMMUNITY-ACQUIRED PNEUMONIA REQUIRIN...
    Medical condition: NEUMONIA ADQUIRIDA EN LA COMUNIDAD QUE REQUIERE HOSPITALIZACION (COMMUNITY-ACQUIRED PNEUMONIA REQUIRING HOSPITALIZATION)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003067-22 Sponsor Protocol Number: PRISTINE Start Date*: 2012-11-19
    Sponsor Name:LUMC
    Full Title: Pneumonia treated with rifampicine attenuates inflammation
    Medical condition: Community acquired pneumonia CURB-65 class >1
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002799-42 Sponsor Protocol Number: CAPstatin2013 Start Date*: 2014-03-27
    Sponsor Name:Dipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma
    Full Title: Statins in the prevention of myocardial damage in pneumonia
    Medical condition: Patients hospitalized with community-acquired pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006951-32 Sponsor Protocol Number: REP0321 Start Date*: 2022-04-05
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multina...
    Medical condition: COVID-19 and other community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022380-35 Sponsor Protocol Number: 982 Start Date*: 2011-06-10
    Sponsor Name:Biotest AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in ...
    Medical condition: severe Community Acquired Pneumonia (sCAP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003854-28 Sponsor Protocol Number: REP-FAR-006 Start Date*: 2008-01-06
    Sponsor Name:Replidyne, Inc.
    Full Title: Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 10 Days Versus Clarithromycin in the Treatment of Community-Acquired P...
    Medical condition: Community-acquired pneumonia. This disease can be defined as an acute lower respiratory tract infection not acquired in a hospital or a long-term care facility.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001239-19 Sponsor Protocol Number: PHRN14-PFD-CAPE_COD Start Date*: 2015-08-14
    Sponsor Name:CHRU de TOURS
    Full Title: Effects of low-dose corticosteroids on survival of severe Community-Acquired Pneumonia
    Medical condition: Severe community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002093-31 Sponsor Protocol Number: T47151 Start Date*: 2012-05-03
    Sponsor Name:Oulu University Hospital
    Full Title: Diagnosis community-acquired pneumonia in emergency unit
    Medical condition: lower respiratory tract infection and pneumonia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002051-10 Sponsor Protocol Number: SHP615-302 Start Date*: 2021-04-13
    Sponsor Name:Takeda Development Center, Americas (TDC Americas)
    Full Title: A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in Community Settings
    Medical condition: Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children, and adolescents (from 3 months to < 18 years)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-004880-29 Sponsor Protocol Number: HUB-INF-RADICAP Start Date*: 2019-10-02
    Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge
    Full Title: Phase IV randomized, controlled, open and multicentre clinical trial with two parallel groups, to assess the impact of integral molecular tests in the antimicrobial use in community-acquired pneumo...
    Medical condition: Community-acquired pneumonia (CAP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003117-18 Sponsor Protocol Number: HUB-INF-ALBUCAP-402 Start Date*: 2019-07-10
    Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge
    Full Title: A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acqui...
    Medical condition: Community-acquired pneumonia (CAP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003486-19 Sponsor Protocol Number: 1.002.20 Start Date*: 2020-10-08
    Sponsor Name:University of Dundee
    Full Title: A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con...
    Medical condition: Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10066724 Acute pneumonia LLT
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    23.0 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-000736-37 Sponsor Protocol Number: 1001 Start Date*: 2022-08-12
    Sponsor Name:Biotest AG
    Full Title: A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneu...
    Medical condition: non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Prematurely Ended) HU (Completed) AT (Ongoing) BE (Ongoing) LV (Ongoing) LT (Ongoing) PT (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004615-45 Sponsor Protocol Number: BPR-PIP-002 Start Date*: 2016-12-02
    Sponsor Name:Basilea Pharmaceutica International Ltd
    Full Title: A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephal...
    Medical condition: Hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10010120 Community acquired pneumonia LLT
    19.0 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001246-26 Sponsor Protocol Number: W-4873-201 Start Date*: 2016-10-07
    Sponsor Name:Wockhardt Bio AG
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treat...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-001766-15 Sponsor Protocol Number: MBL2012 Start Date*: 2013-02-12
    Sponsor Name:Fundación Pública Andaluza para la Gestion de la Investigación en Salud de Sevilla
    Full Title: Impact of azithromycin as an immunomodulator in patients with recurrent pneumonia and deficit of mannose-binding LECITHIN (MBL2012)
    Medical condition: Pediatric patients with recurrent pneumonia and MBL deficiency.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10061598 Immunodeficiency PT
    15.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA